Abstract
The author compares the concepts of ‘”circulation of medicines” and “pharmaceutical activity”. The main content of the text is an analysis of the responsibility of manufacturers for damage caused to the health of citizens by substandard, falsified medicines. The relevance lies in the fact that now, during the pandemic, special attention is being paid to new medicines. Due to the fact that they are a special type of product, they are subject to strict requirements for quality, safety and effectiveness, compliance with which also falls on manufacturers of medicines, which once again underlines the need for clearly defined responsibility of manufacturers of medicines. In conclusion, the author suggests possible changes in the legislation on the responsibility of the manufacturer of medicines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
